ANI PHARMACEUTICALS INC
ANIPDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Yutiq 0.18 MG Drug Implant | Phase 3 | Uveitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ANI PHARMACEUTICALS INC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in ANI PHARMACEUTICALS INC's (ANIP) pipeline across Phase 3. Its lead program is Yutiq 0.18 MG Drug Implant (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ANI PHARMACEUTICALS INC's next FDA catalyst?→
ANI PHARMACEUTICALS INC's (ANIP) next tracked catalyst is a Earnings expected November 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANIP biotech catalysts?→
Add ANIP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ANI PHARMACEUTICALS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.